Latest | F'cast | |
---|---|---|
Div Yield | 1.1% | |
Div Cover | 1.3 | |
Op Mrgn | 11.5% | |
ROCE | 17.5% |
Latest | F'cast | |
---|---|---|
P/E | 71.5 | |
PEG | n/a | |
Pr/Revenue | 4.8 | |
Pr/Book | 2.8 |
Latest | F'cast | |
---|---|---|
Revenue | -4.8% | |
PBT | -13.7% | |
EPS | -18.1% | |
DPS | 2.3% |
Year Ending | Revenue ( m) | Pre-tax ( m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
---|---|---|---|---|---|---|---|---|
31-Dec-19 | 4,680.00 | 960.00 | 422.00¢ | 16.8 | n/a | 0% | 124.00¢ | 1.7% |
31-Dec-20 | 5,052.00 | 880.00 | 387.00¢ | 21.8 | n/a | -8% | 127.00¢ | 1.5% |
31-Dec-21 | 5,777.00 | 1,226.00 | 560.00¢ | 17.9 | 0.4 | +45% | 130.00¢ | 1.3% |
31-Dec-22 | 5,517.00 | 511.00 | 221.00¢ | 33.3 | n/a | -60% | 133.00¢ | 1.8% |
31-Dec-23 | 5,252.00 | 441.00 | 181.00¢ | 43.6 | n/a | -18% | 136.00¢ | 1.7% |
Year Ending | Revenue ( m) | Pre-tax ( m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
---|---|---|---|---|---|---|---|---|
31-Dec-24 | 5,599.36 | 752.58 | 422.25¢ | 30.7 | 0.2 | +133% | 141.61¢ | 0.0% |
31-Dec-25 | 6,329.54 | 1,295.14 | 662.86¢ | 19.5 | 0.3 | +57% | 157.63¢ | 0.0% |
31-Dec-26 | 7,021.35 | 1,709.99 | 827.45¢ | 15.7 | 0.6 | +25% | 145.70¢ | 0.0% |
Copyright © 2024 FactSet Research Systems Inc. All rights reserved.
Belgium's UCB to buy US-based Ra Pharmaceuticals... | 10-Oct-2019 | ShareCast |
Europe close: Stocks mixed after BoE minutes, be... | 17-Dec-2014 | ShareCast |
GSK gets emerging markets boost with UCB deal | 24-Jan-2009 | Telegraph |
UCB confident on drug go-ahead | 21-Aug-2007 | The Scotsman |
Fellner shuffles Acambis board | 08-Mar-2007 | Telegraph |
Currency | Euro |
Share Price | 129.50 |
Change Today | 1.90 |
% Change | 1.49 % |
52 Week High | 129.50 |
52 Week Low | 65.78 |
Volume | 257,310 |
Shares Issued | 194.51m |
Market Cap | 25,188m |
Beta | 0.92 |
Strong Buy | 8 |
Buy | 8 |
Neutral | 4 |
Sell | 1 |
Strong Sell | 0 |
Total | 21 |
Time | Volume / Share Price |
17:35 | 912 @ 129.50 |
17:35 | 121 @ 129.50 |
17:35 | 1,708 @ 129.50 |
17:35 | 1,174 @ 129.50 |
17:35 | 75 @ 129.50 |
You are here: research